CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

NCT05948033 | Recruiting Phase 1

• 1 other identifier: CHN-PLAGH-BT-081
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70 antigen positive Relapsed/Refractory Lymphoma . In this clinical trial, at least 12 eligible patients in dose escalation period will be enrolled to receive 3 doses of CD70-CAR cell therapy according to the "3+3" principle. In dose expansion period, additional at most 21 eligible patients will be enrolled to receive CD70-CAR-T cell therapy at dose of recommended phase 2 dose(RP2D).

Conditions

Lymphoma

Keywords

CD70; Relapsed/Refractory

Outcome Measures

Primary Outcomes (3)

• Incidence of treatment related adverse events（AEs）

  AE is defined as any adverse medical event from the date of randomization to 12 months after CD70-CAR-T cells infusion. Among them, CRS and ICANS were graded according to American Society for Transplantation and Cellular Therapy (ASTCT) criteria. Other AEs were graded according to common terminology criteria for adverse events (CTCAE) v5.0.

  Up to 12 months since the initiation of CD70-CAR-T cell therapy.

• Incidence of dose limiting toxicities (DLTs)

  DLT was defined as CD70-CAR-T cells-related events with onset within first 28 days following infusion: Thedevelopment of Grade (G) 3 or higher grade CRS lasting \> 2 weeks; All G4 non-hematologic toxicities.

  Up to 28 days since the initiation of CD70-CAR-T cell therapy

• Maximum tolerated dose (MTD)

  MTD is defined as the highest dose level of less than or equal to 2 DLT among the 6 subjects finally determined.

  Up to 28 days since the initiation of CD70-CAR-T cell therapy

Secondary Outcomes (7)

• Number and copy number of CD70-CAR-T cells

  Up to 3 years

• Objective response rate (ORR)

  Up to 3 years

• Progression Free Survival (PFS)

  Up to 3 years

• Time to response (TTR)

  Up to 3 years

• Duration of response (DOR)

  Up to 3 years

Study Arms (1)

CD70-targeting CAR-T cells

EXPERIMENTAL

Enrolled participants will be given a preconditioning regimen consisted of fludarabine and cyclophosphamide before the infusion of CD70-CAR T cells. Enrolled patients in this arm will be administered CD70-CAR T cells in 3+3 based escalation manner.

Biological: CD70-targeting CAR-T cells

Interventions

CD70-targeting CAR-T cells BIOLOGICAL

Dose escalation: Dose1 (1×10\^6 cells/kg) ,Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7 cells/kg) Doseexpansion: RP2D Drug: Fludarabine Intravenous fludarabine 25-30 mg/m\^2/day on days 5, -4, and -3. Drug: Cyclophosphamide Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.

CD70-targeting CAR-T cells

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18-75 (inclusive);
• ECOG performance status ≤2 and Estimated life expectancy of more than 3 months;
• Patients with histologically confirmed lymphoma including the following types defined by the World Health Organization(WHO) 2016:HL,Aggressive B-cell non-Hodgkin's lymphoma(Diffuse large B-cell lymphoma,High grade B-cell lymphoma,burkitt's lymphoma,Mantle cell lymph,Anaplastic large cell lymphoma, etc.) and Indolent lymphoma（Including but not limited to follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, etc.）
• Relapse after treatment with ≥2 lines systemic therapy for all the above disease types. Relapse disease is defined as disease progression after last regimen. Refractory disease is defined as no CR tofirst-line therapy:
• PD as best response to first-line therapy, or
• SD as best response after at least 4 cycles of first-line therapy (eg, 4 cycles of R- CHOP), or
• PR as best response after at least 6 cycles and biopsy-proven residual disease or disease progression ≤ 6 months of therapy, or
• Refractory post-autologous stem cell transplant (ASCT) i. Disease progression or relapsed less than or equal to 12 months of ASCT (must have biopsy prove recurrence in relapsed individuals) ii. If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy.
• Individuals must have received adequate prior therapy.
• CD70 antigen expression percentage ≥ 10%.
• Successful leukapheresis assessment and preculture of T cells;
• According to Lugano response criteria 2014, there should be at least one evaluable tumor focus. Evaluable tumor focus was defined as that with the longest diameter of intranodal focus \> 1.5cm, the longest diameter of extranodal focus \> 1.0cm assessed by computed tomography (CT) ormagnetic resonance imaging (MRI).
• Functions of important organs meet the following requirements:ANC≥≥1×10\^9/L; Platelet count ≥50×10\^9/L; Hemoglobin ≥80 g/L;Serum AST and serum ALT, ≤3.0 x ULN (≤5 x ULN for patients with liver metastases); Total serum bilirubin ≤3.0 x ULN); Serum creatinine ≤1.5xULN ; Echocardiography showed left ventricular ejection fraction ≥50%.Pulmonary function: oxygen saturation of blood (SaO2) ≥92% in indoor air environment.

You may not qualify if:

• Pregnancy tests for women of childbearing age shall be negative;Both men and women agreed to use effective contraception during treatment and during the subsequent 1 year.
• Ability to understand and sign a written informed consent documen.
• Subjects are being treated with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment.
• Received cytotoxic chemicals, monoclonal antibodies, or immunotherapy within 4 weeks or 5 half-lives before enrollment;
• Pregnant, lactating, or breastfeeding females;
• Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.
• Known positive test result for human immunodeficiency virus (HIV) oracquired immune deficiency syndrome (AIDS);Active infection of hepatitis B virus (HBV), or hepatitis C virus (HCV);
• History of allergy or intolerance to study drug components;
• Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation;
• Major surgery or trauma occurred within 28 days prior to enrollment, or major side effects have not been recovered.
• Known brain metastases or active central nervous system(CNS) has been involved
• Previous or concurrent cancer within 5 years prior to treatment start except for curatively treated cervical cancer in situ, non-melanoma skin cancer, local prostate cancer after radical surgery ;
• Any serious underlying medical (eg, pulmonary, renal,hepatic,gastrointestinal, or neurological) or psychiatric condition or any issue that would limit compliance with study requirements;
• Vaccination within 30 days of study enrollment;
• Previously received targeting CD70 therapy;

Sponsors & Collaborators

• Chinese PLA General Hospital: lead
• UTC Therapeutics Inc.: collaborator

Study Sites (1)

China

Beijing, Biotherapeutic Department of Chinsese PLA Gereral Hospital, China

RECRUITING

MeSH Terms

Conditions

Lymphoma; Recurrence

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Yangbin Zhao, Ph.D

  UTC Therapeutics Inc.

  STUDY DIRECTOR

Central Study Contacts

Weidong Han, Ph.D

CONTACT

010-66937231; hanwdrsw@sina.com

Yang Liu, M.D

CONTACT

010-66939460; liuyang301blood@163.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of Biotherapeutic Department

Study Record Dates

• First Submitted: July 9, 2023
• First Posted: July 17, 2023
• Study Start: July 15, 2023
• Primary Completion: December 31, 2025
• Study Completion (Estimated): December 31, 2026
• Last Updated: July 17, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)